Medipace is a California-based medical device company developing a sacral nerve stimulation (SNS) therapy for patients with ulcerative colitis.

We are presently selecting clinical sites for our early-feasibility study in the US.

In September 2025, the year-long First-In-Human clinical study was completed (see ClinicalTrials.gov for details). The study tested our unique patented stimulation parameters, and a scientific paper is currently being prepared for publication. 

In October 2025, Medipace was selected as a winner in the Shark Tank Pitch Competition by a panel of VC judges at the Georgia Medtech Innovation Summit. 

We are supported by funding from the National Institutes of Health